McKenna & Cuneo "stay of action" Nicorette petition denied by FDA.
This article was originally published in The Tan Sheet
Executive Summary
NICORETTE EXCLUSIVITY DECISION "STAY OF ACTION" NOT WARRANTED, FDA concludes in an Oct. 31 letter from Center for Drug Evaluation & Research Director Janet Woodcock, MD, to McKenna & Cuneo attorney Gary Yingling. The D.C. law firm, representing an unnamed client, requested in a Feb. 16 citizen petition that if relief sought in its November 1995 petition requesting denial of exclusivity for the OTC smoking cessation chewing gum were turned down, FDA Commissioner David Kessler should "stay issuance of market exclusivity to Nicorette until the completion of judicial review of the agency's decision." FDA says it "does not agree that a stay of action is warranted."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC